ALPMF

Astellas : EMA Accepts Marketing Authorization Application For Fezolinetant

Source from : Business Insider - 1 days ago

Astellas Pharma Inc. said that the European Medicines Agency or EMA has accepted for regulatory review the company's marketing ...See details»

Astellas Pharma Inc. ADR

Source from : Wall Street Journal - 17 days ago

1 Day ALPMY -1.91% DJIA -3.54% S&P 500 -3.90% Health Care/Life Sciences -0.27% Kenji Yasukawa President, CEO & Representative Director Astellas Pharma SpA, Astellas Pharma, Inc. Naoki Okamura ...See details»

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant

Source from : Business Insider - 1 days ago

If authorized by the European Commission, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with ...See details»

Astellas confirms US District Court decision for an interim injunction against Hospira for Lexiscan

Source from : Pharmabiz - 4 days ago

Astellas Pharma Inc. confirms the US District Court for the District of Delaware’s order granting an interim injunction enjoining Hospira from launching its generic version of Lexiscan until October 5 ...See details»

Treatment for hot flushes and night sweats accepted for regulatory review by EMA

Source from : labiotech - 1 days ago

A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization ...See details»

EMA accepts Astellas’ filing for fezolinetant

Source from : The Pharma Letter - 1 days ago

Supporting the filing are results from… • All the news that moves the needle in pharma and biotech. • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of ...See details»

Mixed news for Astellas regarding Lexiscan patent dispute

Source from : The Pharma Letter - 5 days ago

Astellas Pharma (TYO: 4503) saw its share gain 1.6% in early trading, though they drifted back, as it revealed it has won a reprieve in its patent dispute with generics and biosimilar injectables ...See details»

Astellas facing generics to big-selling Lexiscan product in US

Source from : pharmaphorum - 5 days ago

Lexiscan was originally developed by CV Therapeutics, which licensed rights to the drug to Astellas shortly before the Japanese pharma launched a hostile bid for the company – thwarted when it ...See details»

European Medicines Agency Accepts Astellas'...

Source from : Benzinga.com - 1 days ago

If authorized by the European Commission, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause TOKYO, Sept. /PRNewswire/ -- Astellas Pharma ...See details»

Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China

Source from : Yahoo Finance - 26 days ago

4, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in ...See details»

USFDA approves Lupin’s extended release tablets for overactive bladder

Source from : The Financial Express on MSN - 2 days ago

Mirabegron is indicated to treat overactive bladder or neurogenic detrusor overactivity but does not cure these conditions.See details»

Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab

Source from : Nasdaq - 19 days ago

(RTTNews) - Seagen Inc. (SGEN), Astellas Pharma Inc. and Merck (MRK) reported results from the phase 1b/2 EV-103 clinical trial Cohort K investigating PADCEV, or enfortumab vedotin-ejfv ...See details»

Lupin bags USFDA approval for Mirabegron ER tablets to treat overactive bladder

Source from : Daily - 1 days ago

Mirabegron is indicated for treating the overactive bladder or neurogenic detrusor overactivity but does not cure these conditions. Read also: Lupin unveils Sodium Sulfate, Potassium Sulfate and ...See details»

Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Source from : Yahoo Finance - 11 days ago

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 19, 2022 /PRNewswire ...See details»